PharmaVoice Logo

Healthcare Leaders Hub

Merck and Isomorphic Labs Enter into a Strategic Research Collaboration to Discover Small Molecules Against an Oncology Target

PharmaShots

Merck and Isomorphic Labs Enter into a Strategic Research Collaboration to Discover Small Molecules Against an Oncology Target

Shots: Merck (MSD) & Isomorphic Labs have entered into a research collaboration that combines Isomorphic Labs’ AI approach to drug discovery with Merck’s proprietary data resources & discovery experience Isomorphic Labs will perform in silico predictions & deliver molecular designs for small molecule candidates against an oncology target using its drug design engine (IsoDDE), incl.… The post Merck and Isomorphic Labs Enter into a Strategic Research Collaboration to Discover Small Molecules Against an Oncology Target appeared first on PharmaShots.

Read Full Article
Adcendo Reports P-I (ADCElerate1) Data of ADCE-D01 for Advanced Soft Tissue Sarcoma at ENA 2026

PharmaShots

Adcendo Reports P-I (ADCElerate1) Data of ADCE-D01 for Advanced Soft Tissue Sarcoma at ENA 2026

Shots: Adcendo has reported initial data from the ongoing P-I (ADCElerate1) trial evaluating ADCE-D01 (uPARAP-targeting ADC) in 47 previously treated patients with advanced soft tissue sarcoma (STS), presented as a late-breaking oral presentation at ENA 2026 Among 27 response-evaluable patients across 12 STS subtypes receiving ADCE-D01 Q2W, ORR was 30% (8 PRs; 5 confirmed) &… The post Adcendo Reports P-I (ADCElerate1) Data of ADCE-D01 for Advanced Soft Tissue Sarcoma at ENA 2026 appeared first on PharmaShots.

Read Full Article
The NMPA Accepts Harbour BioMed’s IND Application for AI-Enabled LET003 to Treat Overweight or Obesity

PharmaShots

The NMPA Accepts Harbour BioMed’s IND Application for AI-Enabled LET003 to Treat Overweight or Obesity

Shots: China’s NMPA has accepted the IND application for Harbour BioMed’s LET003, a next-gen ACVR2A/2B-targeting mAb developed using its Hu-mAtrIx AI platform, for the treatment of overweight or obesity LET003 is Harbour BioMed’s first AI-enabled drug candidate, designed as a dual ACVR2A/ACVR2B blocker to enhance fat reduction while preserving or improving lean mass, particularly in… The post The NMPA Accepts Harbour BioMed’s IND Application for AI-Enabled LET003 to Treat Overweight or Obesity appeared first on PharmaShots.

Read Full Article
Innogen Pharmaceuticals Enters into an Exclusive Licensing Agreement with Arcera Life Sciences for Efsubaglutide Alfa

PharmaShots

Innogen Pharmaceuticals Enters into an Exclusive Licensing Agreement with Arcera Life Sciences for Efsubaglutide Alfa

Shots: Innogen Pharmaceuticals has entered into an exclusive licensing & commercialization agreement with Arcera Life Sciences, granting Arcera rights to efsubaglutide alfa in selected countries in Africa, Latin America, the Middle East & Eastern Europe, while Innogen retains rights in the RoW Innogen will receive $38M in upfront & near-term milestones, incl. a non-refundable upfront… The post Innogen Pharmaceuticals Enters into an Exclusive Licensing Agreement with Arcera Life Sciences for Efsubaglutide Alfa appeared first on PharmaShots.

Read Full Article
Evotec and Bristol Myers Squibb Receive the US FDA’s Second IND Acceptance Under Their Protein Degradation Partnership

PharmaShots

Evotec and Bristol Myers Squibb Receive the US FDA’s Second IND Acceptance Under Their Protein Degradation Partnership

Shots: Evotec’s strategic protein degradation partnership with Bristol Myers Squibb has received a second IND acceptance from the US FDA; the accepted candidate, a cereblon E3 ligase modulator (CELMoD), is expected to enter a P-I trial in 2027 The first candidate produced under the partnership entered a P-I trial in advanced clear cell renal cell… The post Evotec and Bristol Myers Squibb Receive the US FDA’s Second IND Acceptance Under Their Protein Degradation Partnership appeared first on PharmaShots.

Read Full Article

Sponsored content

Featured promotional

Jeplus.in
Sponsored

Jeplus.in

Purchase All Medicines.Get 10% Offer

News

Latest stories

Pharma Tech

Nov 19, 2026, 4:55 PM

Recursion CEO details novel Phase III endpoint for rare disease drug

The AI-driven biotech has secured FDA alignment on a pivotal trial for its FAP therapy, with a study start planned for 2027.

Pharma Tech

Nov 19, 2026, 4:21 PM

Geopolitical pressures and greater buyer selectivity hamper M&A deal closure rates

Despite substantial M&A activity and capital availability, some companies are struggling to get deals over the line.

PharmaShots

Nov 19, 2026, 4:20 PM

Merck and Isomorphic Labs Enter into a Strategic Research Collaboration to Discover Small Molecules Against an Oncology Target

Shots: Merck (MSD) & Isomorphic Labs have entered into a research collaboration that combines Isomorphic Labs’ AI approach to drug discovery with Merck’s proprietary data resources & discovery experience Isomorphic Labs will perform in silico predictions & deliver molecular designs for small molecule candidates against an oncology target using its drug design engine (IsoDDE), incl.… The post Merck and Isomorphic Labs Enter into a Strategic Research Collaboration to Discover Small Molecules Against an Oncology Target appeared first on PharmaShots.

Pharma Tech

Nov 19, 2026, 3:49 PM

Ellipses Pharma plots London listing that could end British biotech IPO drought

The oncology biotech could go public in a SPAC reverse takeover, though an IPO is not guaranteed.

Pharma Tech

Nov 19, 2026, 3:38 PM

Lineage enters race to Huntington’s market with NeuroAirmid takeover  

Lineage hopes that hNSC-01, a novel cell therapy, could offer symptomatic and disease-slowing benefits in Huntington’s.

Pharma Tech

Nov 19, 2026, 2:33 PM

AbbVie and Disco ink $2.5bn pact for next-generation cancer bispecifics 

The drugs developed through AbbVie and Disco's collaboration will look to address significant unmet needs plaguing the solid tumour space.

News

Latest industry coverage

Google News

Nov 19, 2026, 8:06 PM

GLP-1 drugmaker Novo plans 215 more job cuts in NJ - NJBIZ

GLP-1 drugmaker Novo plans 215 more job cuts in NJ  NJBIZ

Google News

Nov 19, 2026, 7:41 PM

China’s rapid growth in early-stage pharma rattles US - Chemical & Engineering News

China’s rapid growth in early-stage pharma rattles US  Chemical & Engineering News

Google News

Nov 19, 2026, 7:25 PM

Sanofi Pompe drug shortage disrupts U.S. treatments as manufacturing issues persist - Traders Union

Sanofi Pompe drug shortage disrupts U.S. treatments as manufacturing issues persist  Traders Union

Google News

Nov 19, 2026, 7:11 PM

Merck (MRK) Pairs AI Drug Discovery Deal With Nemtabrutinib Phase 3 Exit - Simply Wall St

Merck (MRK) Pairs AI Drug Discovery Deal With Nemtabrutinib Phase 3 Exit  Simply Wall St

Google News

Nov 19, 2026, 7:10 PM

Facing down Dupixent cliff, Sanofi mulls buyout of Insmed and its blockbuster-to-be Brinsupri: Bloomberg - Fierce Pharma

Facing down Dupixent cliff, Sanofi mulls buyout of Insmed and its blockbuster-to-be Brinsupri: Bloomberg  Fierce Pharma

Google News

Nov 19, 2026, 7:05 PM

Executive Conversations: How Should Manufacturers Reevaluate Their Channel Strategy? - Pharmaceutical Commerce

Executive Conversations: How Should Manufacturers Reevaluate Their Channel Strategy?  Pharmaceutical Commerce

Google News

Nov 19, 2026, 6:46 PM

Novartis trims medium-term growth target, shares fall - Reuters

Novartis trims medium-term growth target, shares fall  Reuters

Google News

Nov 19, 2026, 6:39 PM

FDA Drug Advertising Rules: What Pharma Lobbyists Must Know - MultiState

FDA Drug Advertising Rules: What Pharma Lobbyists Must Know  MultiState

Google News

Nov 19, 2026, 6:16 PM

Pharma sector doubles down on AI to slash costs, timelines - Reuters

Pharma sector doubles down on AI to slash costs, timelines  Reuters

Sponsored placement

Featured promotions

Jeplus.in
Sponsored

Jeplus.in

Purchase All Medicines.Get 10% Offer